Current Approaches to the Management of Patients with Endometrial Cancer.

Emmanouil Kalampokas, Georgios Giannis, Theodoros Kalampokas, Angeliki-Astero Papathanasiou, Dimitra Mitsopoulou, Evangelia Tsironi, Olga Triantafyllidou, Mahalakshmi Gurumurthy, David E Parkin, Mary Cairns, Nikolaos F Vlahos
Author Information
  1. Emmanouil Kalampokas: Unit of Gynecologic Oncology, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece. ORCID
  2. Georgios Giannis: Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece. ORCID
  3. Theodoros Kalampokas: Unit of Obstetrics and Gynecology, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece. ORCID
  4. Angeliki-Astero Papathanasiou: Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece. ORCID
  5. Dimitra Mitsopoulou: Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece. ORCID
  6. Evangelia Tsironi: Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
  7. Olga Triantafyllidou: Unit of Obstetrics and Gynecology, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
  8. Mahalakshmi Gurumurthy: Department of Gynaecological Oncology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
  9. David E Parkin: Honorary Consultant Gynaecologist Oncologist, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
  10. Mary Cairns: Department of Gynaecological Oncology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
  11. Nikolaos F Vlahos: Unit of Obstetrics and Gynecology, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece. ORCID

Abstract

The incidence of endometrial cancer (EC) is rising and healthcare professionals need to be informed about the latest data on the constant developments in the field of its management. With particular interest in the classification and management of EC, we surveyed current literature, national and international data, and guidelines, as well as the latest studies to present the most recent data regarding the management of EC. It became evident that despite the consensus on low-risk EC, there are still controversies surrounding the management of high-risk EC, especially regarding the role of sentinel lymph node biopsy (SLNB). Our aim is to present the old and new perspectives in the management of EC, the different available surgical routes, the possible desire for fertility preservation, the role of adjuvant therapies and the focus on the advantages and the limitations of the implementation of SLNB in therapeutic strategies. It became evident throughout our search and based on literature data that minimally invasive surgery (MIS) leads to satisfying outcomes, thus becoming gradually the preferred route of surgery, while SLNB could provide essential information and guidance about the overall management needed in cases of both low-risk and high-risk EC.

Keywords

References

  1. Arch Gynecol Obstet. 2019 May;299(5):1429-1435 [PMID: 30747328]
  2. Obstet Gynecol Clin North Am. 2018 Mar;45(1):155-173 [PMID: 29428283]
  3. Am J Surg Pathol. 2013 Jun;37(6):874-81 [PMID: 23629444]
  4. Cancers (Basel). 2021 Mar 23;13(6): [PMID: 33806979]
  5. Virchows Arch. 2018 Jun;472(6):885-896 [PMID: 29234950]
  6. J Cancer Res Clin Oncol. 2018 Jul;144(7):1385-1393 [PMID: 29691646]
  7. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S40-S63 [PMID: 30550483]
  8. Nature. 2013 May 2;497(7447):67-73 [PMID: 23636398]
  9. J Clin Oncol. 2013 Jul 10;31(20):2607-18 [PMID: 23733771]
  10. Histopathology. 2020 Jan;76(1):52-63 [PMID: 31846532]
  11. Int J Gynaecol Obstet. 2018 Jul;142(1):84-90 [PMID: 29637560]
  12. Gynecol Oncol. 1983 Feb;15(1):10-7 [PMID: 6822361]
  13. Gynecol Oncol. 2018 Feb;148(2):258-266 [PMID: 29217139]
  14. Gynecol Oncol. 2015 Jan;136(1):60-4 [PMID: 25449312]
  15. J Immunother Cancer. 2022 Mar;10(3): [PMID: 35288469]
  16. Lancet Oncol. 2010 Aug;11(8):772-80 [PMID: 20638899]
  17. J Clin Oncol. 2019 Aug 1;37(22):1895-1908 [PMID: 31116674]
  18. CA Cancer J Clin. 2019 Jul;69(4):258-279 [PMID: 31074865]
  19. Gynecol Oncol. 2012 Dec;127(3):651-61 [PMID: 23000148]
  20. Gland Surg. 2020 Dec;9(6):2091-2105 [PMID: 33447560]
  21. Best Pract Res Clin Obstet Gynaecol. 2022 Jan;78:52-63 [PMID: 34420863]
  22. Lancet. 2016 Mar 12;387(10023):1094-1108 [PMID: 26354523]
  23. Eur J Obstet Gynecol Reprod Biol. 2018 May;224:77-80 [PMID: 29554604]
  24. Hum Pathol. 1998 Jun;29(6):551-8 [PMID: 9635673]
  25. Int J Gynecol Cancer. 2016 Jan;26(1):2-30 [PMID: 26645990]
  26. JAMA Surg. 2021 Feb 1;156(2):157-164 [PMID: 33175109]
  27. Eur J Cancer. 2019 Jul;116:77-85 [PMID: 31181536]
  28. Eur J Obstet Gynecol Reprod Biol X. 2019 Jul 10;4:100084 [PMID: 31517308]
  29. Am J Clin Oncol. 2019 Jul;42(7):549-554 [PMID: 31169554]
  30. Acta Obstet Gynecol Scand. 2021 Aug;100(8):1526-1533 [PMID: 33721324]
  31. Gynecol Oncol Res Pract. 2016 Dec 13;3:14 [PMID: 27999680]
  32. Cochrane Database Syst Rev. 2018 Oct 31;10:CD006655 [PMID: 30379327]
  33. Lancet Oncol. 2018 Mar;19(3):295-309 [PMID: 29449189]
  34. Nat Rev Cancer. 2015 Mar;15(3):181-94 [PMID: 25673086]
  35. Gynecol Oncol. 2013 May;129(2):277-84 [PMID: 23485770]
  36. Am J Obstet Gynecol. 2016 Nov;215(5):588.e1-588.e7 [PMID: 27288987]
  37. Gynecol Oncol. 2019 Jun;153(3):496-499 [PMID: 31230614]
  38. Arch Pathol Lab Med. 2013 Nov;137(11):1574-83 [PMID: 24168495]
  39. Lancet Oncol. 2014 Jun;15(7):e268-78 [PMID: 24872110]
  40. Gynecol Oncol. 2022 May;165(2):347-352 [PMID: 35314086]
  41. Gynecol Oncol Rep. 2016 Apr 19;17:69-71 [PMID: 27453926]
  42. Ann Surg Oncol. 2017 Dec;24(13):3981-3987 [PMID: 29058141]
  43. Gynecol Oncol. 2017 Aug;146(2):234-239 [PMID: 28528918]
  44. Int J Gynecol Cancer. 2016 Feb;26(2):407-15 [PMID: 26807569]
  45. Biomark Res. 2021 Jun 16;9(1):49 [PMID: 34134781]
  46. Int J Gynecol Cancer. 2022 Jun 22;: [PMID: 35732351]
  47. Gynecol Oncol. 2019 Jun;153(3):676-683 [PMID: 30952370]
  48. Int J Gynaecol Obstet. 2018 Dec;143(3):313-318 [PMID: 30125949]
  49. Int J Gynecol Cancer. 2020 Mar;30(3):352-357 [PMID: 31911539]
  50. Annu Rev Pathol. 2019 Jan 24;14:339-367 [PMID: 30332563]
  51. Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):496-502 [PMID: 31759077]
  52. J Obstet Gynaecol. 2011;31(1):13-7 [PMID: 21280986]
  53. Virchows Arch. 2021 Feb;478(2):153-190 [PMID: 33604759]
  54. Ecancermedicalscience. 2018 Jan 16;12:798 [PMID: 29434664]
  55. Prz Menopauzalny. 2016 Jun;15(2):63-8 [PMID: 27582678]
  56. CA Cancer J Clin. 2021 Jan;71(1):7-33 [PMID: 33433946]
  57. J Clin Oncol. 2009 Nov 10;27(32):5331-6 [PMID: 19805679]
  58. Endocr Relat Cancer. 2010 Oct 29;17(4):1007-19 [PMID: 20843938]
  59. Int J Gynecol Cancer. 2018 Jan;28(1):139-144 [PMID: 29194192]
  60. J Clin Oncol. 2022 Mar 1;40(7):752-761 [PMID: 34990208]
  61. Gynecol Oncol. 2021 Apr;161(1):122-129 [PMID: 33485641]
  62. Clin Oncol (R Coll Radiol). 2021 Sep;33(9):e372-e382 [PMID: 34053834]
  63. Curr Opin Obstet Gynecol. 2017 Feb;29(1):47-58 [PMID: 27941361]
  64. Nat Rev Cancer. 2019 Sep;19(9):510-521 [PMID: 31388127]
  65. Semin Oncol Nurs. 2019 Apr;35(2):157-165 [PMID: 30867105]
  66. Sisli Etfal Hastan Tip Bul. 2019 Mar 21;53(3):252-255 [PMID: 32377091]
  67. Cancer. 2020 May 15;126(10):2225-2249 [PMID: 32162336]
  68. PLoS One. 2020 Jul 23;15(7):e0236402 [PMID: 32701999]
  69. Front Endocrinol (Lausanne). 2022 May 09;13:783150 [PMID: 35615721]
  70. BMJ Open. 2020 Sep 16;10(9):e036222 [PMID: 32938592]
  71. Ther Adv Med Oncol. 2021 Aug 14;13:17588359211035959 [PMID: 34408794]
  72. Chin Clin Oncol. 2021 Apr;10(2):22 [PMID: 33951918]
  73. Cancers (Basel). 2021 May 26;13(11): [PMID: 34073635]
  74. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-S143 [PMID: 29644661]
  75. Arch Gynecol Obstet. 2020 Feb;301(2):585-590 [PMID: 31781888]
  76. J Clin Oncol. 2019 Jul 20;37(21):1810-1818 [PMID: 30995174]
  77. Clin Transl Oncol. 2015 Oct;17(10):835-9 [PMID: 26260911]
  78. Lancet Oncol. 2017 Mar;18(3):384-392 [PMID: 28159465]
  79. Oncologist. 2019 Dec;24(12):e1381-e1387 [PMID: 31270269]
  80. Gynecol Oncol. 2021 Mar;160(3):817-826 [PMID: 33516529]
  81. Radiol Oncol. 2021 Feb 11;55(2):144-149 [PMID: 33583160]
  82. Am Soc Clin Oncol Educ Book. 2017;37:435-442 [PMID: 28561715]
  83. Eur J Obstet Gynecol Reprod Biol. 2022 Mar;270:50-89 [PMID: 35065448]
  84. Med Hypotheses. 2017 Jun;103:10-20 [PMID: 28571791]
  85. Int J Mol Sci. 2021 Aug 27;22(17): [PMID: 34502183]
  86. Gynecol Oncol. 2017 Dec;147(3):549-553 [PMID: 28942993]
  87. Gynecol Oncol. 2019 Jul;154(1):124-130 [PMID: 31103324]
  88. Nat Rev Clin Oncol. 2011 May;8(5):261-71 [PMID: 21221135]
  89. J Clin Oncol. 2020 Nov 20;38(33):3841-3850 [PMID: 33078978]
  90. Am J Obstet Gynecol. 2016 Jul;215(1):117.e1-7 [PMID: 26743505]
  91. Eur J Surg Oncol. 2021 May;47(5):1117-1123 [PMID: 33268212]
  92. Cochrane Database Syst Rev. 2017 Oct 02;10:CD007585 [PMID: 28968482]
  93. N Engl J Med. 2019 Jun 13;380(24):2317-2326 [PMID: 31189035]
  94. JBRA Assist Reprod. 2016 Dec 01;20(4):232-239 [PMID: 28050959]
  95. Lancet. 2005 Aug 6-12;366(9484):491-505 [PMID: 16084259]
  96. Am J Obstet Gynecol. 2017 May;216(5):459-476.e10 [PMID: 27871836]
  97. Am J Surg Pathol. 2014 Dec;38(12):1583-7 [PMID: 25229772]

Word Cloud

Created with Highcharts 10.0.0ECmanagementdataSLNBendometrialcancerlatestclassificationliteraturepresentregardingbecameevidentlow-riskhigh-riskrolesentinellymphnodebiopsysurgeryincidencerisinghealthcareprofessionalsneedinformedconstantdevelopmentsfieldparticularinterestsurveyedcurrentnationalinternationalguidelineswellstudiesrecentdespiteconsensusstillcontroversiessurroundingespeciallyaimoldnewperspectivesdifferentavailablesurgicalroutespossibledesirefertilitypreservationadjuvanttherapiesfocusadvantageslimitationsimplementationtherapeuticstrategiesthroughoutsearchbasedminimallyinvasiveMISleadssatisfyingoutcomesthusbecominggraduallypreferredrouteprovideessentialinformationguidanceoverallneededcasesCurrentApproachesManagementPatientsEndometrialCancerlymphadenectomy

Similar Articles

Cited By